Effect of Exercise Training on the Function of HDL-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Coronary Artery Disease (HERCET-Study)

NCT ID: NCT00457379

Last Updated: 2007-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with coronary artery disease are characterized by an increased cardiovascular risk and they often have low blood high density lipoprotein (HDL)-cholesterol levels or HDL-cholesterol with modified vasculoprotective properties.

The purpose of the present study is to characterize the quality of HDL-cholesterol in patients with coronary artery disease and normal blood HDL-cholesterol levels and to examine the effect of exercise training on the vasculoprotective effects of HDL-cholesterol in these patients. Additionally, the researchers aim to investigate the endothelial function, oxidative stress and the regenerative capacity of the endothelial progenitor cells in patients with coronary artery disease and the changes dependent on physical activity of patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

physical exercise

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Coronary artery disease
* Normal HDL-cholesterol levels in blood:

* \> 40 mg/dl (1.03 mmol/L) in males
* \> 50 mg/dl (1.29 mmol/L) in females

Exclusion Criteria

* Type 1 or 2 diabetes mellitus
* Acute coronary syndrome
* Unstable angina pectoris
* Myocardial infarction during the last 8 weeks
* Therapy with niacin
* Active infections
* Ventricular arrhythmias
* Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 95 mmHg
* Cancer
* Pregnant or lactating
* Alcoholism
Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hannover Medical School

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Helmut Drexler, MD

Role: STUDY_DIRECTOR

Hannover Medical School

Ulf Landmesser, MD

Role: PRINCIPAL_INVESTIGATOR

Hannover Medical School

Kristina Sonnenschein, MD

Role: PRINCIPAL_INVESTIGATOR

Hannover Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hannover Medical School

Hanover, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ulf Landmesser, MD

Role: CONTACT

+49511532 ext. 2229

Kristina Sonnenschein

Role: CONTACT

+49511532 ext. 5402

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ulf Landmesser, MD

Role: primary

+49511532 ext. 2229

Kristina Sonnenschein

Role: backup

+49511532 ext. 5402

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4031214

Identifier Type: -

Identifier Source: org_study_id